IQ-AI Limited (GB:IQAI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
IQ-AI Limited has shared promising results from their Phase 1 clinical trial of oral gallium maltolate for treating glioblastoma, with some patients showing no disease progression for over six months. The company is preparing for a Phase 2 trial estimated at $2-2.5 million, aiming to start in 2025 with more extensive patient enrollment and a focus on overall survival. IQ-AI holds exclusive rights for commercialization and is looking to strengthen its IP position while considering future partnerships post-Phase 2 success.
For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.